Propofol Inhibits HIF-1α/NLRP3 Signaling Pathway and Mast Cell Activation to Ameliorate Airway Inflammation in Allergic Asthma | Synapse
March 3, 2026
Propofol Inhibits HIF-1α/NLRP3 Signaling Pathway and Mast Cell Activation to Ameliorate Airway Inflammation in Allergic Asthma
Key Points
Airway inflammation is notably improved with propofol treatment in allergic asthma models, resolving existing symptoms.
The competitive binding of propofol to hif-1α inhibits the hif-1α-nlrp3 signaling pathway, reducing mast cell degranulation.
Analysis involved OVA-induced asthma models, demonstrating how propofol affects pathophysiological processes in this condition.
These findings support the need for further exploration of propofol’s role in treating asthma-related inflammation.
Abstract
Propofol markedly improved OVA-induced asthma and inhibited mast cell degranulation by binding competitively to HIF-1α, thereby disrupting the HIF-1α-NLRP3 interaction and attenuating allergic asthma.